Get the Stockscreener App
24.17
0.33%
-0.08
After Hours:
24.23
0.06
+0.25%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.17, with a volume of 26.81M.
It is down -0.33% in the last 24 hours and down -5.59% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.25
Open:
$24.345
24h Volume:
26.81M
Relative Volume:
0.68
Market Cap:
$137.76B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
18.53
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-0.62%
1M Performance:
-5.59%
6M Performance:
-5.14%
1Y Performance:
-6.25%
1-Day Range:
$24.09
$24.41
1-Week Range:
$23.62
$24.41
52-Week Range:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.17 | 138.21B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,188.58 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 623.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 441.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 308.90B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 295.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? - AOL.com
Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure - Yahoo Finance
Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA - Moomoo
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Benzinga
FDA Approves Expanded Use of Pfizer's Padcev (PFE) with Merck's Keytruda - GuruFocus
Pfizer Poised for Mixed Second Quarter, RBC Says - marketscreener.com
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Singapore
Nathan Berman communicating with investors over Pfizer project - The Real Deal
Pfizer wins FDA label expansion for Padcev plus Merck’s Keytruda in bladder cancer - Seeking Alpha
BofA Securities Adjusts Pfizer Price Target to $26 From $27 - marketscreener.com
Pfizer Vaccine Dispute Hits Polish, Romania Air Traffic Agencies - ThePrint
McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait - AOL.com
PFIZER INC : RBC reiterates its Neutral rating - marketscreener.com
Pfizer Seen Reporting Q2 Revenue In Line With Consensus, EPS Below Estimates, RBC Says - marketscreener.com
Polish air traffic control faces funding freeze over COVID vaccine ruling - marketscreener.com
Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is” - Yahoo Finance
This Week’s Leadership Moves: Pfizer, Commonwealth Bank, and GE HealthCare - CDO Magazine
Stability concerns linger at former Pfizer building - PIX11
Stability concerns linger for former Pfizer building - PIX11
Pfizer's Depo-Provera Settlement: What Women With Meningioma Need to Know About the June 2026 Agreement - JD Supra
Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look - simplywall.st
Pfizer Trades at Just 8.5x Earnings While Peers Fetch 16x. Is the Discount Justified? - TIKR.com
Pfizer building inspector, subcontractor’s violations face scrutiny as probes proceed - The Real Deal
Pfizer Fails to Revive $108 Million Cancer-Drug Patent Verdict - Bloomberg Law News
NYC workers continue stabilizing 29 floors of former Pfizer HQ in Midtown. Here's the latest on the investigation. - CBS News
Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative? - Yahoo Finance
AstraZeneca wins appeal in Pfizer patent dispute over Tagrisso By Investing.com - Investing.com Canada
Efforts continue to shore up former Pfizer headquarters after concerns of collapse - CBS News
Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study - TipRanks
BridgeBio hits 52-week high on late-stage trial setback for Astra/ Ionis (update) - Seeking Alpha
‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend - Yahoo Finance
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board - Yahoo Finance Singapore
Pfizer Inc. outlines pipeline priorities as a major U.S. drugmaker - Ad-hoc-news.de
PFE Stock Quote Price and Forecast - CNN
MetroLoft says it has ‘identified the issue’ with the old Pfizer building - PIX11
NCLA to Fifth Circuit: Revive Suit Against Gov’t-Led Censorship of Covid Vaccine-Injured Americans - GlobeNewswire Inc.
Mamdani believes Pfizer building issue was a ‘breakdown’ - pix11.com
Pfizer (PFE) On IBRANCE Approval And Dividend Move Has Valuation Back In Focus - simplywall.st
Pfizer Building Developer Says Buckled Columns Were 'Freak Accident' Caused by Weight of New Addition - Realtor.com
Enterprise value to EBIT forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
Engineering Failure Likely Behind Pfizer Project Scare - The Real Deal
Former Pfizer headquarters now "safe and stable" after steel columns buckled - CBS News
Stabilization efforts continue at old Pfizer building - PIX11
Did the old NYC Pfizer building collapse? Not quite - PIX11
After collapse scare, Pfizer building stabilization efforts continue - The Real Deal
Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval? - Yahoo Finance
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Then vs. Now: Molecular Design - Pfizer
JPMorgan Adjusts Price Target on Pfizer to $28 From $30 - marketscreener.com
How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum - Yahoo Finance
Pfizer Prevnar 20 by Pfizer Inc.adult pneumonia protection pushes vaccine portfolio - AD HOC NEWS
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.72%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):